Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD51 | Q06609 | 5/20 | 0.81 |
| ▸ | RAD1 | O60671 | 1/20 | 0.72 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.72 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.67 |
| ▸ | APEX1 | P27695 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 2/20 | 0.54 |
| ▸ | LTA | P01374 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | SENP3 | Q9H4L4 | 4/20 | 0.42 |
| ▸ | SENP2 | Q9HC62 | 4/20 | 0.42 |
| ▸ | SENP1 | Q9P0U3 | 4/20 | 0.42 |
| ▸ | SUMO2 | P61956 | 3/20 | 0.42 |
| ▸ | SUMO1 | P63165 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351606 | 1.00 | RAD51 (0.81) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL25796 | 1.00 | RAD51 (0.81) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL2333703 | 0.99 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL2333711 | 0.99 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL30160852 | 0.99 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL15823509 | 0.99 | RAD51 (0.80) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL5616054 | 0.92 | RAD51 (0.70) | RAD51RAD1P2RY6ENPP2APEX1 | |
| Acridine SCHEMBL6290391 | 0.90 | RAD51 (0.67) | RAD51RAD1P2RY6ENPP2APEX1 | |
| Acridine SCHEMBL722533 | 0.90 | RAD51 (0.67) | RAD51RAD1P2RY6ENPP2APEX1 | |
| SCHEMBL4857681 | 0.89 | ENPP2 (0.69) | RAD51RAD1P2RY6ENPP2APEX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 814 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11535901-B2 | Probe for detecting and treating virus | YONSEI UNIVERSITY INDUSTRY FOUNDATION (YONSEI UIF) (KR) | 2022-12-27 | — | — | US | claimed |
| US-20190331690-A1 | BIOTHIOL DETECTION COMPOSITION COMPRISING REDOX REGULATION PROTENIN | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY (KR) | 2019-10-31 | — | — | US | claimed |
| US-20190093180-A1 | PROBE FOR DETECTING AND TREATING VIRUS | YONSEI UNIVERSITY INDUSTRY FOUNDATION (YONSEI UIF) (KR) | 2019-03-28 | — | — | US | claimed |
| US-20190000791-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | Board of Supervisors for the University of Louisiana System | 2019-01-03 | — | — | US | claimed |
| EP-2934110-B1 | USE OF CONNEXIN CHANNEL INHIBITORS TO PROTECT GRAFTS | UNIV GENT (BE) | 2018-08-01 | — | — | EP | claimed |
| EP-2671570-B1 | MAGNETIC NANOPARTICLE, HAVING A CURIE TEMPERATURE WHICH IS WITHIN BIOCOMPATIBLE TEMPERATURE RANGE, AND METHOD FOR PREPARING SAME | UNIV KOREA RES & BUS FOUND (KR) | 2018-05-30 | — | — | EP | claimed |
| US-20140024683-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2014-01-23 | — | — | US | claimed |
| EP-2671570-A2 | MAGNETIC NANOPARTICLE, HAVING A CURIE TEMPERATURE WHICH IS WITHIN BIOCOMPATIBLE TEMPERATURE RANGE, AND METHOD FOR PREPARING SAME | Korea University Research and Business Foundation (KR) | 2013-12-11 | — | — | EP | claimed |
| US-20130309702-A1 | MAGNETIC NANOPARTICLE, HAVING A CURIE TEMPERATURE WHICH IS WHITHIN BIOCOMPATIBLE TEMPERATURE RANGE, AND METHOD FOR PREPARING SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2013-11-21 | — | — | US | claimed |
| US-8372593-B2 | Method for detecting misfolded proteins and prions | ADLYFE, INC. (US) | 2013-02-12 | — | — | US | claimed |
| WO-2003008638-A2 | SORTING AND IMMOBILIZATION SYSTEM FOR NUCLEIC ACIDS USING SYNTHETIC BIDNING SYSTEMS | NANOGEN RECOGNOMICS GMBH (DE) | 2003-01-30 | — | — | WO | claimed |
| EP-0620822-B1 | HYBRIDIZATION OF POLYNUCLEOTIDES CONJUGATED WITH CHROMOPHORES AND FLUOROPHORES TO GENERATE DONOR-TO-DONOR ENERGY TRANSFER SYSTEM | NANOTRONICS INC (US) | 2001-05-30 | — | — | EP | claimed |
| EP-1067134-A2 | Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system | NANOTRONICS, INC. (US) | 2001-01-10 | — | — | EP | claimed |
| US-6162603-A | Hybridization of polynucleotides conjugated with chromophores and fluorophores to generate donor-to-donor energy transfer system | NANOGEN, INC. (US) | 2000-12-19 | — | — | US | claimed |
| US-5932614-A | VIRICIDES AGAINST HIV | MERRELL PHARMACEUTICALS INC. (US) | 1999-08-03 | — | — | US | claimed |
| US-5565322-A | PHOTOELECTRIC DEVICES; DETECTORS; MEDICAL DIAGNOSIS | NANOGEN, INC. (US) | 1996-10-15 | — | — | US | claimed |
| US-5532129-A | Self-organizing molecular photonic structures based on chromophore- and fluorophore-containing polynucleotides and methods of their use | ENTERPRISE PARTNERS II, L.P. (US) | 1996-07-02 | — | — | US | claimed |
| US-5494932-A | AIDS, RETROVIRUSES, HERPES VIRUSES, CYTOMEGALOVIRUS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-02-27 | — | — | US | claimed |
| EP-0498095-B1 | Sulfonic stilbene derivatives in the treatment of viral diseases | MERRELL DOW PHARMA (US) | 1995-01-04 | — | — | EP | claimed |
| EP-0498095-A1 | Sulfonic stilbene derivatives in the treatment of viral diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-08-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024683-A1 | CHLORIDE CHANNEL AND CHLORIDE TRANSPORTER MODULATORS FOR THERAPY IN SMOOTH MUSCLE DISEASES | CLCN2, SLC6A1, SLC26A3 | RAD51 4871/4885RAD1 4885/4885P2RY6 709/4885 |
| US-20190000791-A1 | ISOTHIOCYANATOSTILBENES AS A NOVEL METHOD AND PRODUCT FOR TREATING CANCER | SI, PCMT1, HDAC8 | RAD51 4231/4885RAD1 3425/4885P2RY6 3825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.